N-(6-azidohexyl)-4H-thiochromeno[4,3-d][1,3]thiazol-2-amine | 1431658-50-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻喃类
• 英文名称: N-(6-azidohexyl)-4H-thiochromeno[4,3-d][1,3]thiazol-2-amine
• CAS: 1431658-50-2
• 化学式: C₁₆H₁₉N₅S₂
• 分子量: 345.492
• InChiKey: FIABMYWSQCMKEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  23
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  92.8
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  6-azidohexyl 4-methylbenzenesulfonate 、 4H-苯并噻喃并[4,3-d]噻唑-2-胺 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以67%的产率得到N-(6-azidohexyl)-4H-thiochromeno[4,3-d][1,3]thiazol-2-amine
  参考文献：
  名称：

  Tricyclic thiazoles are a new class of angiogenesis inhibitors

  摘要：

  Tricyclic thiazoleamine derivatives that were identified as hits in a screen against human umbilical vein endothelial cell proliferation were subjected to a structure-activity relationship study. Two structurally superimposable scaffolds-4H-thiochromeno[4,3-d]thiazol-2-amine and 5,6-dihydro-4H-benzo[6,7]cyclo hepta[1,2-d] thiazol-2-amine derivatives-yielded low-micromolar inhibitors, and two among them 37 and 43 also exhibited antiangiogenic activity in an endothelial tube formation assay. Thus, 37 and 43 can serve as leads to develop a novel class of antiangiogenic agents. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.02.067

文献信息

• Tricyclic thiazoles are a new class of angiogenesis inhibitors
  作者：Shridhar Bhat、Joong Sup Shim、Jun O. Liu

  DOI：10.1016/j.bmcl.2013.02.067

  日期：2013.5

  Tricyclic thiazoleamine derivatives that were identified as hits in a screen against human umbilical vein endothelial cell proliferation were subjected to a structure-activity relationship study. Two structurally superimposable scaffolds-4H-thiochromeno[4,3-d]thiazol-2-amine and 5,6-dihydro-4H-benzo[6,7]cyclo hepta[1,2-d] thiazol-2-amine derivatives-yielded low-micromolar inhibitors, and two among them 37 and 43 also exhibited antiangiogenic activity in an endothelial tube formation assay. Thus, 37 and 43 can serve as leads to develop a novel class of antiangiogenic agents. (C) 2013 Elsevier Ltd. All rights reserved.